The researchers suggested that the system's combination of speed and high coverage could enable new applications within the imaging mass spec space.
Revenues rose to $521.1 million from $466.6 million in Q3 2018, beating the consensus Wall Street estimate of $496.7 million.
While the approach lost some of its luster after failing to deliver on early hype, technological improvements are revitalizing interest among researchers.
The instrument's ability to run in negative-ion mode allows it to move beyond its traditional focus on proteins and into the analysis of other analyte classes.
More powerful and user-friendly mass spec systems could drive an uptick in interest in the technique, suggested a leading top-down researcher.
The company reported revenues of $490.2 million, up from $443.7 million in Q2 2018 and beating the consensus Wall Street estimate of $477.8 million.
At the recent ASMS annual meeting, vendors including Bruker, Sciex, and Thermo Fisher Scientific presented new versions of the fast-growing mass spec technique.
New instrument releases at this week's meeting reflected proteomics' increased emphasis on throughput and the continuing spread of ion mobility technology.
Bruker signed a codevelopment and comarketing agreement with PreOmics for sample prep, and a partnership with Genedata for proteomics software.
The company also announced that its board of directors has authorized payment of a quarterly cash dividend of $0.04 per share of its common stock.
Forensic genetic firm Verogen has bought the genetic genealogy site GEDmatch.
Researchers have 3D-printed plastic bunnies that encase the information needed to make more such bunnies in DNA, according to Discover magazine.
Dan Rather, the former CBS Evening News anchor and executive producer of a new documentary, writes at the Guardian that everyone needs to know about CRISPR.
In PNAS this week: analysis of FOXA1 upregulation in ER-positive breast cancer, gene editing to correct recessive dystrophic epidermolysis bullosa, and more.